These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: MicroRNA-148a-3p inhibits cancer progression and is a novel screening biomarker for gastric cancer.
    Author: Bao C, Guo L.
    Journal: J Clin Lab Anal; 2020 Oct; 34(10):e23454. PubMed ID: 32785967.
    Abstract:
    PURPOSE: Dysregulation of miR-148a-3p in gastric cancer was reported. However, the diagnostic potential and biological function of miR-148a-3p in gastric cancer progression is not fully studied. METHODS: Bioinformatics analysis and RT-qPCR assay were performed to analyze the expression of miR-148a-3p in gastric cancer tissues and plasma of gastric cancer patients. Receiver operating characteristic curve analysis was performed to analyze the diagnostic value of miR-148a-3p. In vitro proliferation, apoptosis, migration, invasion, sphere formation assay and Western blotting assay were performed to evaluate the biological function of miR-148a-3p in gastric cancer progression. RESULTS: miR-148a-3p was significantly down-regulated in both gastric cancer patients' tissue and plasma samples. Plasma miR-148a-3p showed promising efficacy for gastric cancer diagnosis. Overexpression of miR-148a-3p could inhibit the proliferative phenotype, metastatic phenotype, and cancer stem-like properties of gastric cancer cells. CONCLUSIONS: miR-148a-3p inhibits cancer progression and is a novel diagnostic biomarker for gastric cancer.
    [Abstract] [Full Text] [Related] [New Search]